Trial Profile
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Peginterferon lambda-1a (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- 04 Oct 2021 Status changed from active, no longer recruiting to discontinued.
- 28 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 07 Apr 2021 Planned End Date changed from 30 Sep 2021 to 30 Dec 2021.